Granules receives MPP license to manufacture and market nirmatrelvir in combination with ritonavir

24 Mar 2022 , 01:32 AM

Granules India has received a license from Medicines Patent Pool MPP to manufacture and market generic versions of Pfizers oral treatment nirmatrelvir which will be copackaged with ritonavir for treatment of COVID-19 The licenses are applicable for both active pharmaceutical ingredients API and finished products in tablet form of nirmatrelvir; ritonavir Nirmatrelvir is an inhibitor of SARS-CoV-2 3CL-like protease that prevents polyprotein cleavage of proteins necessary for SARS-CoV-2 genome replication Nirmatrelvir in combination with ritonavir under the Pfizer brand name PAXLOVID is currently approved for emergency use in the US Canada and many other countries for the treatment of mild-to-moderate COVID-19 in certain adults and pediatric patients Nirmatrelvir is an inhibitor of SARS-CoV-2 3CL-like protease that prevents polyprotein cleavage of proteins necessary for SARS-CoV-2 genome replication Nirmatrelvir in combination with ritonavir under the Pfizer brand name PAXLOVID is currently approved for emergency use in the US Canada and many other countries for the treatment of mild-to-moderate COVID-19 in certain adults and pediatric patients